Clinical trial
Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In…
NCT00031278 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00031278 |
|---|---|
| Title | Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast Cancer |
| Official title | A Phase I/II Open Label, Multi-Center Study For The Evaluation Of The Combination Of CpG 7909 And Herceptin® In Patients With Metastatic Breast Cancer |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Metastatic Breast |
| Intervention type | Drug |
| Interventions | CPG 7909, Herceptin® |
| Enrollment | 12 |
| Start date | Oct 1, 2001 |
| Primary completion | Jun 1, 2003 |
| Completion | Jun 1, 2003 |
| First posted | Mar 1, 2002 |
| Last update posted | May 30, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: